- |||||||||| anti-Claudin 18.2 CAR-T cell therapy / First Affiliated Hospital Xi'an Jiaotong University, Legend Biotech
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, CAR T-Cell Therapy, IO biomarker, Metastases: A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jul 1, 2020
P1, N=2, Terminated,
N=18 --> 2 | Trial completion date: Dec 2023 --> Mar 2020 | Recruiting --> Terminated | Trial primary completion date: Mar 2023 --> Mar 2020; the Preliminary data, progress of this study and the adjustment of the pipeline and strategy .
- |||||||||| anti-Claudin 18.2 CAR-T cell therapy / First Affiliated Hospital Xi'an Jiaotong University, Legend Biotech
Enrollment open, CAR T-Cell Therapy, IO biomarker, Metastases: A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - May 7, 2019
P1, N=18, Recruiting,
N=18 --> 2 | Trial completion date: Dec 2023 --> Mar 2020 | Recruiting --> Terminated | Trial primary completion date: Mar 2023 --> Mar 2020; the Preliminary data, progress of this study and the adjustment of the pipeline and strategy . Not yet recruiting --> Recruiting
|
